Best Stocks: Piper Jaffray reiterates its $416 price target and Neutral rating on Regeneron (NASDAQ:REGN); Emisphere (OTC:EMIS), WSI Industries (NASDAQ:WSCI)
Piper Jaffray noted that the U.K.’s National Institute for Health and Care Excellence gave a preliminary recommendation that Regeneron’s (NASDAQ:REGN) EYLEA be available for DME patients “ only with central retinal thickness greater than 400 microns”. The firm added that such a threshold falls above the median thicknesses of the Protocol T cohorts, indicating that less than 50% of DME patients would be covered.…
